Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor …
C Yee, JA Thompson, D Byrd… - Proceedings of the …, 2002 - National Acad Sciences
Adoptive T cell therapy, involving the ex vivo selection and expansion of antigen-specific T
cell clones, provides a means of augmenting antigen-specific immunity without the in vivo …
cell clones, provides a means of augmenting antigen-specific immunity without the in vivo …
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma
T Chodon, B Comin-Anduix, B Chmielowski… - Clinical Cancer …, 2014 - AACR
Purpose: It has been demonstrated that large numbers of tumor-specific T cells for adoptive
cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous …
cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous …
Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma
A Mackensen, N Meidenbauer, S Vogl… - Journal of Clinical …, 2006 - ascopubs.org
Purpose The adoptive transfer of in vitro generated tumor antigen-specific cytotoxic T
lymphocytes (CTL) provides a promising approach to the immunotherapy of cancer. A phase …
lymphocytes (CTL) provides a promising approach to the immunotherapy of cancer. A phase …
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma
ME Dudley, J Wunderlich, MI Nishimura… - Journal of …, 2001 - journals.lww.com
This report describes a phase I study of the adoptive transfer of cloned melanoma antigen–
specific T lymphocytes for therapy of patients with advanced melanoma. Clones were …
specific T lymphocytes for therapy of patients with advanced melanoma. Clones were …
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype
AG Chapuis, JA Thompson… - Proceedings of the …, 2012 - National Acad Sciences
Adoptively transferred tumor-specific T cells offer the potential for non–cross-resistant
therapy and long-term immunoprotection. Strategies to enhance in vivo persistence of …
therapy and long-term immunoprotection. Strategies to enhance in vivo persistence of …
Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.
L Duval, H Schmidt, K Kaltoft, K Fode, JJ Jensen… - Clinical cancer research …, 2006 - AACR
PURPOSE: We did a phase I dose-escalation trial to evaluate the feasibility and safety of
intratumoral injections of C Cure 709, an allogeneic, continuous CTL cell line that, restricted …
intratumoral injections of C Cure 709, an allogeneic, continuous CTL cell line that, restricted …
Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose …
EME Verdegaal, M Visser, TH Ramwadhdoebé… - Cancer Immunology …, 2011 - Springer
Abstract A phase I/II study was conducted to test the feasibility and safety of the adoptive
transfer of tumor-reactive T cells and daily injections of interferon-alpha (IFNα) in metastatic …
transfer of tumor-reactive T cells and daily injections of interferon-alpha (IFNα) in metastatic …
[HTML][HTML] Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones
A Khammari, N Labarrière, V Vignard… - Journal of investigative …, 2009 - Elsevier
Immunotherapy by adoptive T-cell transfer aims at maximizing tumor antigen-specific T-cell
responses. We treated 14 patients at the metastatic stage in a phase II study with Melan-A …
responses. We treated 14 patients at the metastatic stage in a phase II study with Melan-A …
Adoptive cell therapy for the treatment of patients with metastatic melanoma
SA Rosenberg, ME Dudley - Current opinion in immunology, 2009 - Elsevier
Adoptive cell therapy (ACT) is the best available treatment for patients with metastatic
melanoma. In a recent series of three consecutive clinical trials using increasing …
melanoma. In a recent series of three consecutive clinical trials using increasing …
Generation and Purification of CD8+ Melan-A-specific Cytotoxic T Lymphocytes for Adoptive Transfer in Tumor Immunotherapy
M Oelke, U Moehrle, JL Chen, D Behringer… - Clinical Cancer …, 2000 - AACR
Tumor antigens that might serve as potential targets for adoptive T-cell therapy have been
defined in different tumor entities, especially in malignant melanoma. To generate conditions …
defined in different tumor entities, especially in malignant melanoma. To generate conditions …